Enveric Biosciences Receives Two US Patents for Psilocybin Derivatives [Microdose]
Tuesday, December 3, 2024 1 min read
Key Takeaway: Enveric Biosciences has announced the issuance of two new patents from the US Patent and Trademark Office for its EVM301 and EVM201 series compounds. This development brings the total number of patents for the EVM301 series to 11, highlighting the company's progress in the field of psilocybin derivatives.
Price reaction · baseline $58.986 (2024-12-02 close) · hit pre-market · clean, no other ENVB news in the window
day 0 close · peak
+0.6%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences has received two new patents.
The patents support the EVM301 and EVM201 series compounds.
Total patents for the EVM301 series now reach 11.
Full Press Release Details
Enveric Biosciences announced the issuance of two new patents from the US Patent and Trademark Office (USPTO) supporting its EVM301 and EVM201 series compounds. These patents increase the total number of patents to 11 for the EVM301 series.
Full Article >>
Frequently Asked Questions
What patents did Enveric Biosciences receive?
Enveric Biosciences received two new patents for its EVM301 and EVM201 series compounds.
How many patents does the EVM301 series have now?
The EVM301 series now has a total of 11 patents.
Which office issued the patents?
The patents were issued by the US Patent and Trademark Office (USPTO).